Close Menu
    Facebook X (Twitter) Instagram
    The Northeast's Top Manufacturing Resource
    • Advertise
    • Free Subscription
    • Press Submission
    • Contact Us
    Facebook X (Twitter) Instagram LinkedIn
    The Gateway to New England Manufacturing
    NEW ENGLAND MANUFACTURING
    • Manufacturing News
      • Industry Spotlight
      • News & Press
    • Company Directory
    • About Us
    • Past Issues
    • Featured Companies
    • Advertise
    ADVERTISING INFO
    Facebook X (Twitter) Instagram
    The Gateway to New England Manufacturing
    Home » Thermo Fisher Scientific Expands Cell And Gene Therapy Capabilities
    News & Press

    Thermo Fisher Scientific Expands Cell And Gene Therapy Capabilities

    gatewayadminBy gatewayadminOctober 13, 2022Updated:October 13, 2022No Comments4 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Thermo Fisher Scientific, the world leader in serving science, today expanded its cell and gene therapy capabilities with the opening of its new previously announced viral vector manufacturing facility in Plainville, Mass. The 300,000 square foot, state- of-the-art site will add approximately 300 jobs to support the development, testing and manufacture of viral vectors, which are critical components in the development and commercialization of gene therapies.

    “Thermo Fisher Scientific’s new, state-of-the-art viral vector manufacturing facility in Plainville is a clear statement from a world-class company that the Commonwealth is not just the leader in R&D, but also in bio-manufacturing. I will continue to work closely with Thermo Fisher as they create jobs and help cure disease.”

    “Plainville is an impressive addition to our pharma services network as we continue to invest and innovate cell and gene therapy services, products and workflows,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “We are enabling our customers to speed their scientific discoveries in cell and gene therapy while also supporting their manufacturing needs, whether they are early in the development process or ready to transition to clinical or commercial scale.”

    The new cGMP-compliant Plainville facility significantly expands the company’s clinical and commercial viral vector capacity to six sites in the U.S and Europe. The site features sustainable construction design, flexible laboratory and production suites, adjacent warehousing, and office space, as well as Thermo Fisher’s advanced bioproduction and analytical instrumentation technologies.

    “Massachusetts is fortunate to have an industry-leading company like Thermo Fisher Scientific headquartered in our state, contributing to our growing life sciences, biotech and manufacturing sectors and creating high-quality jobs,” said Governor Charlie Baker. “Thermo Fisher Scientific’s new manufacturing facility in Plainville will be one of the largest of its kind and will deepen the company’s ties and expand its employee footprint in Massachusetts.”

    “Massachusetts is the world capital of life sciences, with a footprint of biomedical innovation that extends well beyond Cambridge and Boston,” said Congressman Jake Auchincloss. “Thermo Fisher Scientific’s new, state-of-the-art viral vector manufacturing facility in Plainville is a clear statement from a world-class company that the Commonwealth is not just the leader in R&D, but also in bio-manufacturing. I will continue to work closely with Thermo Fisher as they create jobs and help cure disease.”

    The new Plainville facility is part of an investment strategy to provide customers with fully integrated capabilities that connect the entire cell and gene therapy value chain — from early development and clinical scale-up to commercial manufacturing. These include translational sciences labs for early-stage development; plasmid DNA manufacturing; viral vector services; cell therapy manufacturing; and, integrated commercial packaging and distribution services. With over 20 years of experience in cGMP viral vector manufacturing, the company has produced more than 130 viral vector products used to develop treatments for cancer, blood disorders and other genetic diseases.

    In addition, the new Patheon Quick to Clinic viral vector is an all-inclusive manufacturing platform utilizing optimized, Investigational New Drug-ready processes for lentivirus and adeno-associated virus manufacturing to allow rapid process development, de-risk regulatory pathway and accelerates timeline from discovery to clinic. With the addition of the Plainville site, Thermo Fisher now has more than 3,500 employees at more than 15 facilities supporting various businesses in the Commonwealth. Open job positions can be found at jobs.thermofisher.com.

    About Thermo Fisher Scientific
    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    gatewayadmin

    Related Posts

    Going Green in the Metals Industry: How can Businesses Achieve Sustainable Practices?

    March 16, 2026

    Mastercam Enhances Direct Customer Support with the Acquisition of Key Assets of QTE Manufacturing Solutions

    November 20, 2025

    CO2 Laser Lenses For Cutting Precision Seals

    November 14, 2025
    Find A Company News & Press
    Read the Latest Issue
    Archive Issue

    Issue 314

    By gatewayadminFebruary 16, 2026

    The Gateway Gets Results

    Advertise in The Gateway Today!

    Advertising Info
    • Industry Spotlight
    • News & Press
    • Company Directory
    • About Us
    • Past Issues
    • Featured Companies
    • Advertise
    • Email Sign Up

    Call Today:
    877-463-4020

    Over 20 Years
    Facebook X (Twitter) Instagram LinkedIn
    © 2026 Built by Boldwerks.

    Type above and press Enter to search. Press Esc to cancel.

    Complete this form for more information on advertising in The Gateway

    Press Release Submission Form

    Fill out the form below or email press direct to chris@thegatewaymag.com


    Press Release Submissions

    Email Signup
    Free Subscription

    Subscribe

    • This field is for validation purposes and should be left unchanged.